{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:09:07Z","timestamp":1787972947889,"version":"build-2784847793"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":261,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.mce.2019.110539","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T11:28:23Z","timestamp":1565695703000},"page":"110539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress"],"prefix":"10.1016","volume":"498","author":[{"given":"Tamiris Ingrid","family":"Petito-da-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-9569","authenticated-orcid":false,"given":"Vanessa","family":"Souza-Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Barbosa-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib1","first-page":"363","article-title":"Dietary effect of different high-fat diet on rat liver stereology","volume":"23","author":"Aguila","year":"2003","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"11","key":"10.1016\/j.mce.2019.110539_bib2","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1248\/bpb.b13-00351","article-title":"Expression of hepatic fat-specific protein 27 depends on the specific etiology of fatty liver","volume":"36","author":"Aibara","year":"2013","journal-title":"Biol. Pharm. Bull."},{"issue":"12","key":"10.1016\/j.mce.2019.110539_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10715762.2015.1078461","article-title":"Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease","volume":"49","author":"Ashraf","year":"2015","journal-title":"Free Radic. Res."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/hepr.12138","article-title":"Liver damage is not reversed during the lean period in diet-induced weight cycling in mice","volume":"44","author":"Barbosa-da-Silva","year":"2014","journal-title":"Hepatol. Res. : the official journal of the Japan Society of Hepatology"},{"issue":"8","key":"10.1016\/j.mce.2019.110539_bib5","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/db07-1383","article-title":"Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance","volume":"57","author":"Bell","year":"2008","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.mce.2019.110539_bib6","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1053\/j.gastro.2010.02.051","article-title":"Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice","volume":"138","author":"Bieghs","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol. : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib9","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097118","article-title":"Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice","volume":"9","author":"Carr","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00428-011-1147-1","article-title":"A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies","volume":"459","author":"Catta-Preta","year":"2011","journal-title":"Virchows Arch. : an international journal of pathology"},{"issue":"6","key":"10.1016\/j.mce.2019.110539_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2012.128","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"107","author":"Chalasani","year":"2012","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbalip.2018.02.003","article-title":"FTO promotes SREBP1c maturation and enhances CIDEC transcription during lipid accumulation in HepG2 cells","volume":"1863","author":"Chen","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"3","key":"10.1016\/j.mce.2019.110539_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3803\/EnM.2018.33.3.387","article-title":"Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease","volume":"33","author":"Choi","year":"2018","journal-title":"Endocrinology and metabolism"},{"issue":"11","key":"10.1016\/j.mce.2019.110539_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","article-title":"SREBP transcription factors: master regulators of lipid homeostasis","volume":"86","author":"Eberle","year":"2004","journal-title":"Biochimie"},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.mce.2019.110539_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3164\/jcbn.09-83","article-title":"A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL\/6 mice fed a high fat diet","volume":"46","author":"Fraulob","year":"2010","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib20","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.mce.2019.110539_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med. Mol. Morphol."},{"issue":"9","key":"10.1016\/j.mce.2019.110539_bib22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1091\/mbc.E16-01-0039","article-title":"Transcription factor ATF4 directs basal and stress-induced gene expression in the unfolded protein response and cholesterol metabolism in the liver","volume":"27","author":"Fusakio","year":"2016","journal-title":"Mol. Biol. Cell"},{"issue":"9","key":"10.1016\/j.mce.2019.110539_bib23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.nutres.2015.06.012","article-title":"Prosteatotic genes are associated with unsaturated fat suppression of saturated fat-induced hepatic steatosis in C57BL\/6 mice","volume":"35","author":"Geng","year":"2015","journal-title":"Nutr. Res."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cmet.2013.08.019","article-title":"AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation","volume":"18","author":"Gowans","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.mce.2019.110539_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and mechanisms of nonalcoholic fatty liver disease","volume":"78","author":"Haas","year":"2016","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.mce.2019.110539_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mce.2019.110539_bib27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic reticulum stress and the inflammatory basis of metabolic disease","volume":"140","author":"Hotamisligil","year":"2010","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/osp4.294","article-title":"Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study","volume":"4","author":"Itani","year":"2018","journal-title":"Obes Sci Pract"},{"issue":"1","key":"10.1016\/j.mce.2019.110539_bib29","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1038\/s41598-017-12106-y","article-title":"Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis","volume":"7","author":"Iuchi","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12576-010-0127-6","article-title":"Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats","volume":"61","author":"Iwata","year":"2011","journal-title":"J. Physiol. Sci."},{"key":"10.1016\/j.mce.2019.110539_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndrome"},{"issue":"7","key":"10.1016\/j.mce.2019.110539_bib32","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metab. Clin. Exp."},{"issue":"1\u20133","key":"10.1016\/j.mce.2019.110539_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2011.09.172","article-title":"Inhibition of stearoyl-CoA desaturase1 activates AMPK and exhibits beneficial lipid metabolic effects in vitro","volume":"672","author":"Kim","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2019.110539_bib35","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and alpha-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes","author":"Kim","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4093\/dmj.2019.0034","article-title":"Nonalcoholic fatty liver disease and diabetes: Part II: treatment","volume":"43","author":"Kim","year":"2019","journal-title":"Diabetes & metabolism journal"},{"issue":"3","key":"10.1016\/j.mce.2019.110539_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.mce.2019.110539_bib38","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mce.2019.110539_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.mce.2019.110539_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/oby.20123","article-title":"Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease","volume":"21","author":"Larter","year":"2013","journal-title":"Obesity"},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib41","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2011.10.018","article-title":"Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets","volume":"56","author":"Li","year":"2012","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.mce.2019.110539_bib42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1590\/S0001-37652003000400006","article-title":"Stereological tools in biomedical research","volume":"75","author":"Mandarim-de-Lacerda","year":"2003","journal-title":"An. Acad. Bras. Cienc."},{"issue":"3","key":"10.1016\/j.mce.2019.110539_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1248\/bpb.33.346","article-title":"A physiological role for fat specific protein 27\/cell death-inducing DFF45-like effector C in adipose and liver","volume":"33","author":"Matsusue","year":"2010","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2008.03.003","article-title":"Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27","volume":"7","author":"Matsusue","year":"2008","journal-title":"Cell Metabol."},{"issue":"8","key":"10.1016\/j.mce.2019.110539_bib48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00210-015-1134-1","article-title":"A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib49","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"issue":"9972","key":"10.1016\/j.mce.2019.110539_bib50","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mce.2019.110539_bib51","first-page":"2808","article-title":"FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets","volume":"118","author":"Nishino","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mce.2019.110539_bib52","first-page":"686","volume":"vol. 47","author":"Ojima","year":"2015"},{"key":"10.1016\/j.mce.2019.110539_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.06.006","article-title":"Effects of dapagliflozin and\/or insulin glargine on beta cell mass and hepatic steatosis in db\/db mice","volume":"98","author":"Omori","year":"2019","journal-title":"Metab. Clin. Exp."},{"issue":"6","key":"10.1016\/j.mce.2019.110539_bib54","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1113\/JP277140","article-title":"Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions","volume":"597","author":"Orlicky","year":"2019","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.mce.2019.110539_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.cdd.4401373","article-title":"Roles of CHOP\/GADD153 in endoplasmic reticulum stress","volume":"11","author":"Oyadomari","year":"2004","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.mce.2019.110539_bib56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mce.2019.110539_bib57","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/jn\/123.11.1939","article-title":"AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet","volume":"123","author":"Reeves","year":"1993","journal-title":"J. Nutr."},{"issue":"10","key":"10.1016\/j.mce.2019.110539_bib58","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI0216784","article-title":"Translational control in the endoplasmic reticulum stress response","volume":"110","author":"Ron","year":"2002","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.mce.2019.110539_bib59","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.mce.2019.110539_bib60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-8587(14)70004-X","article-title":"Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes","volume":"2","author":"Scheen","year":"2014","journal-title":"The lancet Diabetes & endocrinology"},{"key":"10.1016\/j.mce.2019.110539_bib61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox biology"},{"issue":"6","key":"10.1016\/j.mce.2019.110539_bib62","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/hep.22268","article-title":"Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis","volume":"47","author":"Straub","year":"2008","journal-title":"Hepatology"},{"issue":"1\u20133","key":"10.1016\/j.mce.2019.110539_bib63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.mce.2019.110539_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbaexp.2005.01.017","article-title":"A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein","volume":"1728","author":"Targett-Adams","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.mce.2019.110539_bib65","first-page":"83","article-title":"Diagnostic and treatment implications of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"15","author":"Wong","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.mce.2019.110539_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"7203","key":"10.1016\/j.mce.2019.110539_bib67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature07203","article-title":"From endoplasmic-reticulum stress to the inflammatory response","volume":"454","author":"Zhang","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mce.2019.110539_bib68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cell.2008.07.043","article-title":"Hypothalamic IKKbeta\/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity","volume":"135","author":"Zhang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.mce.2019.110539_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fgene.2014.00112","article-title":"ER stress and hepatic lipid metabolism","volume":"5","author":"Zhou","year":"2014","journal-title":"Front. Genet."},{"issue":"22","key":"10.1016\/j.mce.2019.110539_bib70","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720719302412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720719302412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:08:03Z","timestamp":1759586883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720719302412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":70,"alternative-id":["S0303720719302412"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2019.110539","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2019.110539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110539"}}